The most common adverse effects reported in at least 20% of patients treated with the inavolisib-based regimen were decreased neutrophils, decreased hemoglobin, increased fasting glucose, decreased platelets, decreased lymphocytes, stomatitis, diarrhea, decreased calcium, fatigue, decreased potassium, increased creatinine, increased alanine aminotransferase levels, nausea, decreased sodium, decreased magnesium, rash, decreased appetite, COVID-19 infection, and headache. In the updated OS analysis, no new safety signals were observed.
visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb visitweb